Related Experiment Video

Updated: May 11, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Perspectives on treatment of metastatic castration-resistant prostate cancer

Axel S Merseburger1, Joaquim Bellmunt, Cheryl Jenkins

  • 1Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany. merseburger.axel@mh-hannover.de

The Oncologist
|May 15, 2013
PubMed

Insights

New agents like cabazitaxel and abiraterone acetate are transforming metastatic castration-resistant prostate cancer (mCRPC) treatment. New strategies are needed to match patients with the best novel drugs for improved outcomes.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) management is evolving rapidly.
  • Several novel therapeutic agents are now available and under investigation.

Purpose of the Study:

  • To summarize recent data on novel agents for mCRPC.
  • To discuss current and future treatment strategies for mCRPC.

Main Methods:

  • This review summarizes discussions from a European Treatment Practices Meeting.
  • Focuses on novel agents including cabazitaxel, abiraterone acetate, enzalutamide, and radium-223.

Main Results:

  • New agents are significantly altering the treatment landscape for mCRPC.
  • There is a growing need for predictive biomarkers to guide treatment selection.

Conclusions:

  • The advent of new drugs necessitates updated treatment paradigms in mCRPC.
  • Further research is required to optimize patient selection for novel therapies.
Keywords:
Abiraterone acetateCabazitaxelDocetaxelEnzalutamideMetastatic castration-resistantProstate cancerTreatment

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...